CartaBio
About CartaBio
CartaBio is a Healthcare company based in Wilmington (United States). Live cell imaging solutions are delivered via an AI-based platform. It operates in the Healthcare and Technology sectors. Its chief executive, as recorded, is Robert Yang. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Image Analysis.
Company details
CartaBio is headquartered in Wilmington, United States, with operations centered in the biotech industry. An AI-based platform is developed to provide live cell imaging solutions. Focus is placed on AI-integrated technologies, including scission accelerated fluorophore exchange and the multimodal CellBERT model. These tools are applied to support biotech applications, enabling advanced cellular analysis and research workflows.
- Headquarters Wilmington, United States
- SectorsHealthcareTechnology
- InvestorsDann Capital
& 2 more
Funding Insights of CartaBio
- Total Rounds 1
- Investors Count 3
All 1 funding rounds of CartaBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | Angel Round | – | – |
3 investors in total: 3 institutional.
Investors in CartaBio
CartaBio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Dann Capital, Coho and Industry Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| danencap.com | ||||
| cohovc.com | ||||
| industrycapital.com |
Investor details for CartaBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CartaBio
1 people are tracked at CartaBio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Robert Yang | CEO | Leadership |
Complete people profiles for CartaBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as CartaBio (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CartaBio
CartaBio is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Robert Yang is the CEO of CartaBio, as recorded in our data.
CartaBio is headquartered in Wilmington, United States, with operations centered in the biotech industry. An AI-based platform is developed to provide live cell imaging solutions. Focus is placed on AI-integrated technologies, including scission accelerated fluorophore exchange and the multimodal CellBERT model. These tools are applied to support biotech applications, enabling advanced cellular analysis and research workflows.
CartaBio has 3 investors. Key investors include Dann Capital, Coho, and Industry Capital.